Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak

As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of lymphopenia increased in COVID-19 and there was a sig...

Descripción completa

Detalles Bibliográficos
Autor principal: Tanriverdi, Ozgur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180657/
https://www.ncbi.nlm.nih.gov/pubmed/32333196
http://dx.doi.org/10.1007/s12032-020-01376-8
_version_ 1783525870394146816
author Tanriverdi, Ozgur
author_facet Tanriverdi, Ozgur
author_sort Tanriverdi, Ozgur
collection PubMed
description As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of lymphopenia increased in COVID-19 and there was a significant relationship between lymphopenia and mortality. This can be thought of as an unresponsive problem in how to maintain anti-cancer drugs that cause lymphopenia. This article was written for a hypothetical approach in cancer patients diagnosed with COVID-19 in order to be an idea of collecting data for treatment with anti-cancer drugs that cause lymphopenia.
format Online
Article
Text
id pubmed-7180657
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-71806572020-04-24 Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak Tanriverdi, Ozgur Med Oncol Letter to the Editor As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of lymphopenia increased in COVID-19 and there was a significant relationship between lymphopenia and mortality. This can be thought of as an unresponsive problem in how to maintain anti-cancer drugs that cause lymphopenia. This article was written for a hypothetical approach in cancer patients diagnosed with COVID-19 in order to be an idea of collecting data for treatment with anti-cancer drugs that cause lymphopenia. Springer US 2020-04-24 2020 /pmc/articles/PMC7180657/ /pubmed/32333196 http://dx.doi.org/10.1007/s12032-020-01376-8 Text en © Springer Science+Business Media, LLC, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Letter to the Editor
Tanriverdi, Ozgur
Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak
title Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak
title_full Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak
title_fullStr Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak
title_full_unstemmed Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak
title_short Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak
title_sort lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the covid-19 outbreak
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180657/
https://www.ncbi.nlm.nih.gov/pubmed/32333196
http://dx.doi.org/10.1007/s12032-020-01376-8
work_keys_str_mv AT tanriverdiozgur lymphopeniathatmaydevelopinpatientstreatedwithtemozolomideandimmunecontrolcheckpointinhibitormaybeahighriskformortalityduringthecovid19outbreak

Ejemplares similares